In a meta-analysis of published studies enrolling patients with acromegaly to receive long-acting somatostatin analogues for at least 3 months’ duration, adjuvant treatment with octreotide LAR achieved GH levels <2.5 μg/L in 57 % of patients and normal IGF-1 in 67 % [40]. This evidence concerns the gene IGF1 and acromegaly.